Compounds > evernic acid
Page last updated: 2024-12-05

evernic acid

Description

Evernic acid is a depside, a type of lichen secondary metabolite. It is found in various species of lichens, particularly in the genus *Evernia*. It has been studied for its potential antimicrobial, antioxidant, and anti-inflammatory activities. Evernic acid's synthesis in lichens involves a complex series of enzymatic reactions, starting with simple phenolic compounds. The molecule exhibits a unique structure with two phenolic rings linked by an ester bond. It has shown inhibitory effects against bacteria, fungi, and viruses. Research on evernic acid is ongoing to explore its potential therapeutic applications in medicine and pharmaceuticals.'

evernic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10829
CHEMBL ID1484978
CHEBI ID111284
SCHEMBL ID2552354
MeSH IDM0144968

Synonyms (45)

Synonym
2eq5w5403j ,
3-10-00-01488 (beilstein handbook reference)
unii-2eq5w5403j
evernic acid, pruiss
DIVK1C_006742
nsc 81164
4-((4-methoxy-6-methylsalicyloyl)oxy)-6-methylsalicylic acid
einecs 208-658-2
brn 2227186
benzoic acid, 2-hydroxy-4-((2-hydroxy-4-methoxy-6-methylbenzoyl)oxy)-6-methyl-
2,6-cresotic acid, 4-methoxy-, 4-ester with 6-methyl-beta-resorcylic acid
2,6-cresotic acid, 4-methoxy-, 4-ester with 6-methyl-beta-resorcylate
wln: qr cq e1 dvovr bq f1 do1
evernic acid
benzoic acid, 2-hydroxy-4-[(2-hydroxy-4-methoxy-6-methylbenzoyl)oxy]-6-methyl-
2, 4-methoxy-, 4-ester with 6-methyl-.beta.-resorcylate
nsc81164
nsc-81164
537-09-7
OPREA1_749224
MLS001049100
smr000386932
KBIO1_001686
SPECPLUS_000646
CHEBI:111284
2-hydroxy-4-(2-hydroxy-4-methoxy-6-methylbenzoyl)oxy-6-methylbenzoic acid
NCGC00246189-01
CHEMBL1484978
HMS2267A10
AKOS015969692
REGID_FOR_CID_10829
AB00053221-08
2-hydroxy-4-(2-hydroxy-4-methoxy-6-methyl-benzoyl)oxy-6-methyl-benzoic acid
SCHEMBL2552354
Q27190901
DTXSID20201956
mfcd00045824
CCG-231001
2,6-cresotic acid, 4-methoxy-, 4-ester with 6-methyl-.beta.-resorcylic acid
2,6-cresotic acid, 4-methoxy-, 4-ester with 6-methyl-.beta.-resorcylate
evernsaure
evernicacid
bdbm50491952
CS-0081796
HY-121362

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" decussata and their plasma-related bioavailability were also investigated using LC-ESI-MS/MS."( New Insights into the Biological Activity of Lichens: Bioavailable Secondary Metabolites of Umbilicaria decussata as Potential Anticoagulants.
Javad Davarpanah, S; Vaez, M, 2021)		0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carbonyl compoundAny compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency19.01150.007215.758889.3584AID588342
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency10.00000.28189.721235.4813AID2326
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency56.23413.548119.542744.6684AID743266
DNA polymerase betaHomo sapiens (human)Potency89.12510.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency44.66840.133725.412989.1251AID588795
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency70.79460.010323.856763.0957AID2662
gemininHomo sapiens (human)Potency0.51740.004611.374133.4983AID624296
Alpha-synucleinHomo sapiens (human)Potency35.48130.56239.398525.1189AID652106
Guanine nucleotide-binding protein GHomo sapiens (human)Potency28.18381.995325.532750.1187AID624288
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency44.66843.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Enoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12IC50 (µMol)90.00000.00501.576510.0000AID751284
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (96)

Processvia Protein(s)Taxonomy
lipid biosynthetic processEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
fatty acid elongationEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
protein homotetramerizationEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
fatty acid biosynthetic processEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
biotin biosynthetic processEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
fatty acid elongationEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
response to antibioticEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
enoyl-[acyl-carrier-protein] reductase (NADH) activityEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
protein bindingEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
oxidoreductase activityEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
identical protein bindingEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
NADH bindingEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
cytosolEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
membraneEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
protein-containing complexEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
catalytic complexEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID751284Inhibition of Escherichia coli FabI using 2-dodecenoyl-CoA as substrate at pH 82013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751294Antiplasmodial activity against liver stage of Plasmodium berghei ANKA expressing GFP infected in human Huh7.5 cells assessed as reduction in PB18S gene expression after 48 hrs by qRT-PCR analysis2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751281Antibacterial activity against Escherichia coli ATCC 87392013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751279Hepatotoxicity in zebrafish larva expressing fabp10a:DsRed2 assessed as reduction in liver size at 60.2 uM measured at 6 days postfertilization by fluorescence microscopic analysis2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751276Hepatotoxicity in zebrafish larva expressing fabp10a:DsRed2 assessed as change in liver size at 3.6 to 60.2 uM measured at 6 days postfertilization by fluorescence microscopic analysis relative to control2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751288Inhibition of Plasmodium falciparum FabG using acetoacetyl-CoA as substrate2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751285Inhibition of Staphylococcus aureus FabI using dodecenoyl ACP at pH 7.82013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751295Cytotoxicity against human Huh7.5 cells after 24 hrs by Cell-titerGlo luminescence assay2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751287Inhibition of Plasmodium falciparum FabZ using crotonoyl-CoA as substrate preincubated for 10 mins prior to substrate addition2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751293Antiplasmodial activity against liver stage of Plasmodium berghei ANKA expressing GFP infected in human Huh7.5 cells assessed as decrease in size at 10 uM after 48 hrs by immunofluorescence analysis2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751289Inhibition of Plasmodium falciparum FabI using crotonoyl-CoA as substrate preincubated for 10 mins prior to substrate addition2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751280Toxicity in zebrafish larva measured at 4 days postfertilization2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751286Inhibition of Mycobacterium tuberculosis FabI using 2-dodecenoyl-CoA as substrate at pH 6.82013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751296Cytotoxicity against human KB cells after 72 hrs by Alamar Blue assay2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751291Antiplasmodial activity against blood stage of chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 after 48 hrs by [3H]-hypoxanthine incorporation assay2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.17)18.7374
1990's0 (0.00)18.2507
2000's2 (8.33)29.6817
2010's14 (58.33)24.3611
2020's7 (29.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.19 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.17%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.		2.3110methylpyridines;
phenylpyridine;
tetrahydropyridine		neurotoxin
primaquine
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.		2.0810aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
triclosan
[no description available]		2.0810aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
usnic acid
[no description available]		8.570benzofurans
mannitol
[no description available]		2.3110mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
orcinol
orcinol: used as reagent for pentoses, lignin, beet sugar, saccharoses, arabinose & diastase; RN given refers to parent cpd; structure. orcinol : A 5-alkylresorcinol in which the alkyl group is specified as methyl.		2.08105-alkylresorcinol;
dihydroxytoluene		Aspergillus metabolite
psoromic acid
psoromic acid: structure in first source		2.0810carbonyl compound
epigallocatechin gallate
epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.		2.0810flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
atranorin
atranorin: RN given refers to parent cpd; structure given in first source		2.9740carbonyl compound
orsellinic acid
orsellinic acid: from the Sonoran desert endophytic fungus Chaetomium globosum; structure in first source. o-orsellinic acid : A dihydroxybenzoic acid that is 2,4-dihydroxybenzoic acid in which the hydrogen at position 6 is replaced by a methyl group.		2.5920dihydroxybenzoic acid;
resorcinols		fungal metabolite;
marine metabolite;
metabolite
lobaric acid
lobaric acid: inhibits formation of leukotrienes C4, D4, and E4; also reduces muscle contraction; structure in first source		3.7120carbonyl compound
diffractaic acid
difractaic acid: from Lichen, Usnea steineri; active against Gram-positive, multidrug-resistant bacteria; structure in first source		8.0840carbonyl compound
lecanoric acid
lecanoric acid: from a strain of Pyricularia (deuteromycetes); RN given refers to parent cpd; structure		3.350benzoate ester
gyrophoric acid
gyrophoric acid: a tridepside isolated from Parmelia nepalensis		2.0510carbonyl compound
barbatic acid
barbatic acid: structure in first source		2.5520carbonyl compound
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		3.570
atranol
atranol: an oak moss allergen		2.3110hydroxybenzaldehyde
(+)-usnic acid
[no description available]		2.0810usnic acid
salazinic acid
salazinic acid: lichen metabolite; structure in first source		3.8930
norstictic acid
norstictic acid: from Xanthoparmelia chlorochroa; structure in first source		3.3510
salicylates
Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.		4.6570monohydroxybenzoateplant metabolite
vulpinic acid
vulpinic acid: RN given refers to cpd without isomeric designation; structure given in first source; vulpinic acid refers to (E)-isomer		2.7830butenolide
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.5520
Infections, Plasmodium
[description not available]		02.0810
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		02.0810
Cancer of Colon
[description not available]		02.4110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.4110
Breast Cancer
[description not available]		07.610
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.610
Idiopathic Parkinson Disease
[description not available]		02.3110
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		02.3110
Chronic Illness
[description not available]		04.4511
Calcaneal Spur
[description not available]		04.4511
Anasarca
[description not available]		04.4511
Chronic Plantar Fasciitis
[description not available]		04.4511
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		04.4511
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		04.4511
Fasciitis, Plantar
Inflammation of the plantar fascia (APONEUROSIS) on the bottom of the foot causing heel pain. The etiology of plantar fasciitis remains controversial but is likely to involve a biomechanical imbalance. Though often presenting along with HEEL SPUR, they do not appear to be causally related.		04.4511
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.1710
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		02.1310
Benign Neoplasms
[description not available]		02.0510
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0510
Contact Dermatitis
[description not available]		01.9610
Actinic Reticuloid Syndrome
[description not available]		01.9610
Agricultural Worker Disease
[description not available]		01.9610
Dermatitis, Contact
A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.		01.9610
chemdatabank.com